Skip to content
Quant500 - Quantitative Analysis
Search ticker or company...
ES | EN

Company Profile: West Pharmaceutical Services, Inc. (WST)

WST insider trades (13 months) →

$406.99 −0.22% vs. previous close · Market cap $28.35B

Today's multi-factor rank: 164 of 461 · see the ranking

Quant500 Scores
Momentum
6.3/10
Value
3.9/10
Growth
4.7/10
Quality
5.5/10
Multifactor
5.1/10

Market and Valuation

Price & Market

Prev Close Price:$407.88
Open:$407.39
Day's Low:$406.05
Day's High:$416.23
Bid / Ask:-
Market Cap:28.35B
Enterprise Value:28.26B

52-Week Range

52-Week Low:$223.83
52-Week High:$438.27
Current position in 52-week range
52w Low-52w High
50-Day Avg:$368.70
200-Day Avg:$314.02

Volume

Volume Today:1,075,736
Avg Volume (3m):584,681
Avg Volume (10d):914,650
52-Week Change:+42.15%
vs S&P 500, 52 weeks:-
Beta:1.14

Valuation Multiples

P/E (trailing):45.68

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.

P/E (forward):39.16
PEG Ratio:2.96
Price / Book:9.57
Price / Sales (TTM):8.35
EV / Revenue:8.32
EV / EBITDA:29.40

Dividends

Current yield:0.26%
Annual Dividend Rate:$1.04
Dividend Trailing:$0.88
Yield Trailing:0.22%
5-Year Avg Yield:0.25%
Payout Ratio:9.88%
Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-
Fiscal Year (Next):-

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):3.40B
Gross Profit:1.28B
EBITDA:961.30M
Net Income (TTM):638.90M
Rev Growth (YoY):+8.70%
Earnings Growth (YoY):+57.30%
Quarterly earnings growth (YoY):+52.90%

Margins

Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-

Per Share

EPS Trailing (TTM):$8.91

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$10.39
Revenue Per Share:$47.57
Cash Per Share:-
Book Value:$42.52
Last Dividend:-
Ex-Dividend Date:-
Last Split:-

Balance Sheet & Liquidity

Total cash:464.10M
Total Debt:313.90M
Net Debt (Debt - Cash):−150.20M (net cash)
Debt / Equity:10.58%
Current Ratio:2.82
Quick Ratio:1.91

Cash Flows

Operating Cash Flow:654.50M
Free Cash Flow (FCF):345.56M
FCF Yield (FCF / Market Cap):-
Enterprise Value:28.26B
EV / Revenue:8.32
EV / EBITDA:29.40

Profitability

ROE (Return on Equity):21.23%
ROA (Return on Assets):11.89%
P/E (trailing):45.68
P/E (forward):39.16
Price / Book:9.57
PEG Ratio:2.96
52-Week Change:+42.15%
S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$8.91

Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$10.39
P/E (forward):39.16
PEG Ratio:2.96

Growth and Margins

Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-

Per Share

Revenue Per Share:$47.57
Cash Per Share:-
Book Value:$42.52

Cash Flows (TTM)

Free Cash Flow:345.56M
Operating Cash Flow:654.50M
EBITDA:961.30M
Total Revenue (TTM):3.40B
Net Income (TTM):638.90M
Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter Period Actual EPS Estimated EPS Difference Surprise % Currency

Ownership Structure

Ownership Distribution

% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:69,661,036
Float (free shares):69,134,399
Short interest (shares):2,013,684
Short % of float:-
Short Ratio (days to cover):3.38
Short interest, prior month:-
Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization Report Date % Shares No. Shares Value (USD) Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund Report Date % Shares No. Shares Value (USD) Change %

Recent Insider Trades

Executive / Insider Title Date Action Shares

Options Chain

CALLS

StrikeLastBidAskVol.O.I.IV

PUTS

StrikeLastBidAskVol.O.I.IV

West Pharmaceutical Services, Inc. (WST) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type Date Official link
10-Q2026-10-29View filing ↗
8-K2026-10-26View filing ↗
10-Q2026-07-23View filing ↗
8-K2026-07-14View filing ↗
8-K2026-06-01View filing ↗
8-K/A2026-05-20View filing ↗
SD2026-05-13View filing ↗
8-K2026-05-11View filing ↗
8-K2026-05-05View filing ↗
8-K2026-04-23View filing ↗

Company and Executive Profile

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

General Information

Headquarters:United States
City:Exton
Employees:10,000
Sector:Healthcare
Industry:Medical Instruments & Supplies
Website:-

Key Executives

NameTitleAgeTotal pay
Mr. Robert W. McMahon C.M.A.Senior VP & CFO564.50M
Ms. Annette F. FavoriteChief HR Officer & Senior VP60927,847
Mr. Shane A. CampbellSVP & Chief Proprietary Segment Officer45949,834
Mr. Michel LagardePresident, CEO & Director50-
Mr. Chad R. WintersVP of Finance & Chief Accounting Officer46-
Dr. Devesh MathurSenior VP & CTO--
Mr. Norman D. Finch Jr.Senior VP, General Counsel & Corporate Secretary60-
Ms. Michele PolinskyVice President of Global Communications--

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

West Pharmaceutical Services, Inc. (WST): Quantitative Analysis

West Pharmaceutical Services, Inc. (WST) — Healthcare — Medical Instruments & Supplies. WST is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, WST has returned +48.2% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

WST ranks 164 of 461 on today's multifactor score, and 19 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.78, ranked 90 of 494); its weakest is value (Z -0.68, ranked 443 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

FactorZ-ScoreRank
Multifactor0.061164 of 461
Momentum0.77590 of 494 ↑7
Value-0.678443 of 489 ↓1
Quality0.301117 of 468 ↓1
Growth-0.155239 of 489

Market data

MetricValue
Price$406.99
Market Cap28.35B
P/E45.68
Revenue (last 12 months)3.40B
Price / book9.57
Book value per share$42.52
52-week range$223.83 – $438.27
Dividend yield0.26%
Beta1.14
Average volume584,681
Shares outstanding69.66M
Short interest (% of float)3.38% (as of Oct 15, 2026)

When does WST report earnings? 12 of its last 12, before the open →

What are WST insiders doing? 48 transactions filed with the SEC, of them 6 sells, the last one on Sep 15, 2026 →

WST latest SEC filings

Filing dates on EDGAR, the SEC's public registry. All WST filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about West Pharmaceutical Services (WST)

When does West Pharmaceutical Services report earnings?

West Pharmaceutical Services has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 29, 2026). WST earnings dates and times, quarter by quarter →

What is West Pharmaceutical Services's P/E ratio?

West Pharmaceutical Services's P/E (price over earnings per share for the last twelve months) is 45.7 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: West Pharmaceutical Services is above its sector median. Healthcare stocks, company by company →

Where does West Pharmaceutical Services rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, West Pharmaceutical Services ranks 164 of 461, and 19 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have West Pharmaceutical Services insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of West Pharmaceutical Services shares from August 2025 through Nov 3, 2026. The latest sale was on Sep 15, 2026, by an officer, for $921k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 6 sales by directors, officers and large shareholders. All WST insider trades →

Does West Pharmaceutical Services pay a dividend?

Yes. Its dividend yield is 0.26% at the Nov 3, 2026 close (annual dividend of $1.04 per share). The next announced ex-dividend date is Nov 10, 2026.

What sector is West Pharmaceutical Services in, and which index?

West Pharmaceutical Services is classified in the Healthcare sector (industry: Medical Instruments & Supplies), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

The model portfolio, weekly in your inbox

Every Saturday, its week in one minute: how it went, the best and the worst, and which insiders bought with their own money. Plus, the day the model is rebuilt, which stocks come in and which go out. A simulation, not advice. At most one email a week, no ads, no account; one-click unsubscribe. Made by one person: Pol Gracia.

A model portfolio with simulated results, not a personalized recommendation. Your email is used for this only: privacy.

S&P 500 market gravity